» Articles » PMID: 33255770

Metabolome of Cerebral Thrombi Reveals an Association Between High Glycemia at Stroke Onset and Good Clinical Outcome

Overview
Journal Metabolites
Publisher MDPI
Date 2020 Dec 1
PMID 33255770
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the fact that glucose is the main fuel of the brain, hyperglycemia at hospital admission is generally associated with a poor functional outcome in stroke patients. This paradox may be explained by the lack of information about the blood glucose level at stroke onset. Here, we analyzed the metabolome of blood cells entrapped in cerebral thrombi to gain insight into their metabolism at stroke onset. Fourty-one consecutive stroke patients completely recanalized by mechanical thrombectomy within 6 h were included. The metabolome of retrieved thrombi was analyzed by liquid chromatography tandem with mass spectrometry. Discriminant Analysis (sparse Partial Least Squares Discriminant Analysis (sPLS-DA)) was performed to identify classification models and significant associated features of favorable clinical outcome at 3 months (modified Rankin Scale (mRS) < 2). sPLS-DA of the metabolomes of cerebral thrombi discriminated between stroke patients with a favorable or poor clinical outcome (Area Under the Curve (AUC) = 0.992 (0.931-1)). In addition, our results revealed that high sorbitol and glucose levels in the thrombi positively correlated with favorable clinical outcomes. Sorbitol, a short-term glycemic index reflecting a high blood glucose level at stroke onset, was found to be an independent predictor of good outcome (AUC = 0.908 (0.807-0.995)). This study demonstrates that a high blood glucose level at stroke onset is beneficial to the clinical outcome of the patient.

Citing Articles

Metabolite signature in acute ischemic stroke thrombi: a systematic review.

Arul S, Ghozy S, Mereuta O, Senol Y, Orscelik A, Kobeissi H J Thromb Thrombolysis. 2023; 56(4):594-602.

PMID: 37580625 PMC: 11178128. DOI: 10.1007/s11239-023-02869-9.


Metabolomic Signatures of Scarff-Bloom-Richardson (SBR) Grade in Non-Metastatic Breast Cancer.

Bailleux C, Chardin D, Gal J, Guigonis J, Lindenthal S, Graslin F Cancers (Basel). 2023; 15(7).

PMID: 37046602 PMC: 10093598. DOI: 10.3390/cancers15071941.


Advancing Stroke Research on Cerebral Thrombi with Omic Technologies.

Costamagna G, Bonato S, Corti S, Meneri M Int J Mol Sci. 2023; 24(4).

PMID: 36834829 PMC: 9961481. DOI: 10.3390/ijms24043419.


Unexplored Roles of Erythrocytes in Atherothrombotic Stroke.

Papadopoulos C, Anagnostopoulos K, Tsiptsios D, Karatzetzou S, Liaptsi E, Lazaridou I Neurol Int. 2023; 15(1):124-139.

PMID: 36810466 PMC: 9944955. DOI: 10.3390/neurolint15010011.


Clot Composition Analysis as a Diagnostic Tool to Gain Insight into Ischemic Stroke Etiology: A Systematic Review.

Aliena-Valero A, Baixauli-Martin J, Torregrosa G, Tembl J, Salom J J Stroke. 2021; 23(3):327-342.

PMID: 34649378 PMC: 8521257. DOI: 10.5853/jos.2021.02306.

References
1.
Rosso C, Baronnet F, Diaz B, Le Bouc R, Polara G, Moulton E . The silver effect of admission glucose level on excellent outcome in thrombolysed stroke patients. J Neurol. 2018; 265(7):1684-1689. PMC: 6022525. DOI: 10.1007/s00415-018-8896-6. View

2.
Schurr A . Bench-to-bedside review: a possible resolution of the glucose paradox of cerebral ischemia. Crit Care. 2002; 6(4):330-4. PMC: 137460. DOI: 10.1186/cc1520. View

3.
Siesjo B . Acidosis and ischemic brain damage. Neurochem Pathol. 1988; 9:31-88. DOI: 10.1007/BF03160355. View

4.
Ntaios G, Papavasileiou V, Bargiota A, Makaritsis K, Michel P . Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2013; 9(4):489-93. DOI: 10.1111/ijs.12225. View

5.
Piironen K, Putaala J, Rosso C, Samson Y . Glucose and acute stroke: evidence for an interlude. Stroke. 2012; 43(3):898-902. DOI: 10.1161/STROKEAHA.111.631218. View